Fed’s Powell opens door to potential rate cuts at Jackson Hole
Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), a pharmaceutical company with a market capitalization of $1.01 billion, recently executed a series of stock transactions, according to a recent SEC filing. On March 24, Hohl sold 1,000 shares of common stock at a weighted average price of $22.50, amounting to a total sale of approximately $22,504. This sale was part of a pre-established trading plan under Rule 10b5-1. According to InvestingPro data, analysts have set price targets ranging from $33 to $42 for the stock.
In addition to the sale, Hohl exercised stock options to acquire 1,000 shares at an exercise price of $2.48 per share. Following these transactions, Hohl holds 23,000 shares of Enliven Therapeutics directly.
These transactions reflect Hohl’s ongoing management of his equity holdings in the pharmaceutical company, which is headquartered in Boulder, Colorado.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.